Cefaclor into the millennium.
We review the discovery and development of the cephalosporins and subsequently cefaclor. Cefaclor is active against a wide range of commonly encountered bacterial pathogens, acting by inhibiting cell wall synthesis. Its in vitro activity compares favourably with other beta-lactam antibiotics. Its pharmacokinetic properties indicate that an 8-hourly dosing schedule is appropriate. In addition a delayed release formulation allowing twice daily dosage has been developed. The efficacy of both formulations of cefaclor has been verified by many clinical trials. Cefaclor has been widely used in infections of the respiratory tract (including otitis media), urinary tract and soft tissues. The results of therapy are summarized. The low incidence of adverse events is highlighted and the beneficial influence of this on compliance is described. Finally, the pharmaco-economics of cefaclor are considered.
Brumfitt
W
W
Department of Medical Microbiology, Royal Free Hospital and Royal Free and University College Medical School, London, UK.
Hamilton-Miller
J M
JM
D001424:Bacterial Infections / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D002433:Cefaclor / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002511:Cephalosporins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017850:Economics, Pharmaceutical; D017753:Ecosystem; D006801:Humans; D008826:Microbial Sensitivity Tests; D010349:Patient Compliance
D002511:Cephalosporins; D002433:Cefaclor